X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs PFIZER - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB PFIZER DR. REDDYS LAB/
PFIZER
 
P/E (TTM) x 31.5 34.5 91.3% View Chart
P/BV x 3.4 5.1 66.5% View Chart
Dividend Yield % 0.8 0.7 116.2%  

Financials

 DR. REDDYS LAB   PFIZER
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-18
PFIZER
Mar-18
DR. REDDYS LAB/
PFIZER
5-Yr Chart
Click to enlarge
High Rs2,7882,365 117.9%   
Low Rs1,9021,625 117.0%   
Sales per share (Unadj.) Rs860.8430.3 200.1%  
Earnings per share (Unadj.) Rs57.178.7 72.5%  
Cash flow per share (Unadj.) Rs122.093.2 130.9%  
Dividends per share (Unadj.) Rs20.0020.00 100.0%  
Dividend yield (eoy) %0.91.0 85.1%  
Book value per share (Unadj.) Rs757.7586.5 129.2%  
Shares outstanding (eoy) m165.9145.75 362.6%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.74.6 58.8%   
Avg P/E ratio x41.125.3 162.1%  
P/CF ratio (eoy) x19.221.4 89.8%  
Price / Book Value ratio x3.13.4 91.0%  
Dividend payout %35.025.4 137.9%   
Avg Mkt Cap Rs m389,03491,271 426.2%   
No. of employees `00023.52.6 894.4%   
Total wages/salary Rs m32,1493,143 1,022.9%   
Avg. sales/employee Rs Th6,070.87,484.8 81.1%   
Avg. wages/employee Rs Th1,366.61,195.0 114.4%   
Avg. net profit/employee Rs Th402.51,369.1 29.4%   
INCOME DATA
Net Sales Rs m142,81019,685 725.5%  
Other income Rs m1,5521,143 135.8%   
Total revenues Rs m144,36220,828 693.1%   
Gross profit Rs m23,5125,003 470.0%  
Depreciation Rs m10,772663 1,626.0%   
Interest Rs m7884 18,761.9%   
Profit before tax Rs m13,5045,479 246.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m3440-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m4,3801,878 233.2%   
Profit after tax Rs m9,4683,601 262.9%  
Gross profit margin %16.525.4 64.8%  
Effective tax rate %32.434.3 94.6%   
Net profit margin %6.618.3 36.2%  
BALANCE SHEET DATA
Current assets Rs m104,98424,167 434.4%   
Current liabilities Rs m68,9389,544 722.3%   
Net working cap to sales %25.274.3 34.0%  
Current ratio x1.52.5 60.1%  
Inventory Days Days7455 135.0%  
Debtors Days Days10429 360.9%  
Net fixed assets Rs m104,3859,514 1,097.2%   
Share capital Rs m830458 181.4%   
"Free" reserves Rs m124,88626,375 473.5%   
Net worth Rs m125,71626,832 468.5%   
Long term debt Rs m25,08925 100,356.0%   
Total assets Rs m225,44336,900 611.0%  
Interest coverage x18.11,305.5 1.4%   
Debt to equity ratio x0.20 21,419.3%  
Sales to assets ratio x0.60.5 118.7%   
Return on assets %4.59.8 46.6%  
Return on equity %7.513.4 56.1%  
Return on capital %9.720.4 47.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m72,62322 324,209.8%   
Fx outflow Rs m18,9161,489 1,270.6%   
Net fx Rs m53,707-1,466 -3,662.8%   
CASH FLOW
From Operations Rs m18,0303,318 543.4%  
From Investments Rs m-14,883-2,383 624.5%  
From Financial Activity Rs m-4,440-1,104 402.4%  
Net Cashflow Rs m-1,236-169 733.5%  

Share Holding

Indian Promoters % 25.5 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 5.4 7.5 72.0%  
FIIs % 35.3 4.9 720.4%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 23.7 64.6%  
Shareholders   75,885 85,207 89.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   GSK PHARMA  JUBILANT LIFE SCIENCES  DISHMAN PHARMA  IPCA LABS  NATCO PHARMA  

Compare DR. REDDYS LAB With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Down 1%; Realty, Auto Stocks Tank(12:30 pm)

After opening the day flat share markets in India are trading on a negative note and are presently trading below the dotted line.

Related Views on News

WOCKHARDT LTD. Plunges by 5%; BSE HEALTHCARE Index Down 1.9% (Market Updates)

Sep 24, 2018 | Updated on Sep 24, 2018

WOCKHARDT LTD. share price has plunged by 5% and its current market price is Rs 588. The BSE HEALTHCARE is down by 1.9%. The top gainers in the BSE HEALTHCARE Index are BLISS GVS PHARMA (up 1.0%) and THYROCARE TECHNOLOGIES (up 1.0%). The top losers are WOCKHARDT LTD. (down 5.0%) and PFIZER (down 6.1%).

NAVA BHARAT VENTURES Plunges by 5%; BSE 500 Index Down 1.8% (Market Updates)

Sep 24, 2018 | Updated on Sep 24, 2018

NAVA BHARAT VENTURES share price has plunged by 5% and its current market price is Rs 130. The BSE 500 is down by 1.8%. The top gainers in the BSE 500 Index are CYIENT LTD (up 4.3%) and TCS (up 3.4%). The top losers are NAVA BHARAT VENTURES (down 5.1%) and PFIZER (down 5.7%).

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Sep 24, 2018 01:47 PM

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 8-QTR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS